Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis

Ozgul Muneyyirci-Delale*, David F. Archer, Charlotte D. Owens, Kurt T. Barnhart, Linda D. Bradley, Eve Feinberg, Veronica Gillispie, Sandra Hurtado, Jin Hee Kim, Alice Wang, Hui Wang, Elizabeth A. Stewart

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. Design: Pooled analysis of two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials (Elaris Uterine Fibroids [UF]-1 and UF-2). Setting: A total of 153 gynecological clinical care settings in the United States and Canada. Patient(s): Premenopausal women (18–51 years) with >80 mL of menstrual blood loss (MBL)/cycle and uterine fibroids with and without coexisting adenomyosis diagnosed by ultrasound and/or magnetic resonance imaging at baseline. Intervention(s): Participants were randomized 1:1:2 to placebo, elagolix 300 mg twice daily alone, or elagolix 300 mg twice daily with estradiol 1 mg/norethindrone acetate 0.5 mg once daily. Main Outcome Measure(s): The primary endpoint was the proportion of women who had <80 mL of MBL during the final month and ≥50% reduction in MBL from baseline to the final month. Adverse events were monitored. Result(s): Of 786 women treated across the two trials, 16% (126 women) had coexisting adenomyosis. Among this subset, a significantly greater proportion of women who received elagolix with add-back therapy (77.1% [95% confidence interval, 66.2, 88.0]) met both primary endpoint criteria compared with women who received placebo (12.2% [95% confidence interval, 1.0, 23.4]). Adverse events most frequently reported in the elagolix with add-back adenomyosis subset were hot flushes (18.3%), nausea (11.7%), and night sweats (8.3%). Conclusion(s): Elagolix with add-back therapy significantly reduced heavy menstrual bleeding in women with uterine fibroids and coexisting adenomyosis, suggesting that elagolix efficacy was not adversely affected by the presence of adenomyosis (Elaris UF-1 and UF-2 Clinical-Trials.gov numbers, NCT02654054 and NCT02691494).

Original languageEnglish (US)
Pages (from-to)338-346
Number of pages9
JournalF and S Reports
Volume2
Issue number3
DOIs
StatePublished - Sep 2021

Keywords

  • Adenomyosis
  • elagolix
  • uterine fibroids

ASJC Scopus subject areas

  • Embryology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Fingerprint

Dive into the research topics of 'Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis'. Together they form a unique fingerprint.

Cite this